TG THERAPEUTICS, INC. 10-K

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES. Market Information Our common stock is listed on the Nasdaq Capital Market and trades under the symbol “TGTX”. Holders The number of record holders of our common stock as of February 24, 2021 was 235. Dividends We have never declared or paid any cash dividends on our common stock and do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our board of directors. Securities Authorized for Issuance Under Equity Compensation Plans The following table provides information as of December 31, 2020, regarding the securities authorized for issuance under our equity compensation plan, the TG Therapeutics, Inc. Amended and Restated 2012 Incentive Plan. Equity Compensation Plan Information ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of ​ ​ ​ ​ ​ ​ securities ​ ​ ​ ​ ​ ​ remaining ​ ​ ​ ​ ​ ​ available for ​ ​ Number of ​ ​ ​ future issuance ​ ​ securities to be ​ ​ ​ under equity ​ ​ issued upon ​ Weighted-average ​ compensation ​ ​ exercise of ​ exercise price of ​ plans (excluding ​ ​ outstanding ​ outstanding ​ securities reflected Plan Category ​ options ​ options ​ in column 1) ​ ​ ​ ​ ​ ​ ​ ​ Equity compensation plans approved by security holders ​ 2,526,166 ​ $ 6.99 ​ 4,054,913 Equity compensation plans not approved by security holders ​ — ​ ​ — ​ — Total ​ 2,526,166 ​ $ 6.99 ​ 4,054,913 ​ For information about all of our equity compensation plans see Note 5 to our Consolidated Financial Statements included in this report. 77 Table of Contents COMMON STOCK PERFORMANCE GRAPH The following graph compares the cumulative total stockholder return on our common stock for the period from December 31, 2015 through December 31, 2020, with the cumulative total return over such period on (i) the U.S. Index of The Nasdaq Stock Market and (ii) the Biotechnology Index of The Nasdaq Stock Market. The graph assumes an investment of $100 on December 31, 2015, in our common stock (at the adjusted closing market price) and in each of the indices listed above, and assumes the reinvestment of all dividends. Measurement points are December 31 of each year. ​ * $100 invested on December 31, 2015 in stock or index, including reinvestment of dividends. Fiscal Years ending December 31. 78 Table of Contents ITEM 6. SELECTED FINANCIAL DATA. The following Statement of Operations Data for the years ended December 31, 2020, 2019, 2018, 2017 and 2016, and Balance Sheet Data as of December 31, 2020, 2019, 2018, 2017 and 2016, as set forth below are derived from our audited consolidated financial statements. Audited financial statements prior to 2018 are not contained herein. This financial data should be read in conjunction with “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Item 8. Financial Statements and Supplementary Data.” ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands, except per share information) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years ended December 31, ​ 2020 2019 2018 2017 2016 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ License revenue ​ $ 152 ​ $ 152 ​ $ 152 ​ $ 152 ​ $ 152 ​ ​ ​ ​ ​ ​ Costs and expenses: ​ ​ ​ ​ ​ Research and development: ​ ​ ​ ​ ​ Noncash stock expense associated with in-licensing agreements ​ — ​ 100 ​ 4,000 ​ — ​ — Noncash compensation ​ 13,962 ​ 5,811 ​ 5,598 ​ 5,647 ​ 2,742 Other research and development ​ 151,934 ​ 148,269 ​ 149,793 ​ 96,886 ​ 66,490 Total research and development ​ 165,896 ​ 154,180 ​ 159,391 ​ 102,533 ​ 69,232 ​ ​ ​ ​ ​ ​ General and administrative: ​ ​ ​ ​ ​ Noncash compensation ​ 66,327 ​ 5,523 ​ 7,288 ​ 10,298 ​ 4,767 Other general and administrative ​ 41,523 ​ 9,504 ​ 7,873 ​ 6,033 ​ 5,122 Total general and administrative ​ 107,850 ​ 15,027 ​ 15,161 ​ 16,331 ​ 9,889 ​ ​ ​ ​ ​ ​ Total costs and expenses ​ 273,746 ​ 169,207 ​ 174,552 ​ 118,864 ​ 79,121 ​ ​ ​ ​ ​ ​ Operating loss ​ (273,594) ​ (169,055) ​ (174,400) ​ (118,712) ​ (78,969) ​ ​ ​ ​ ​ ​ Other (income) expense: ​ ​ ​ ​ ​ Interest expense ​ 6,329 ​ 5,287 ​ 877 ​ 845 ​ 886 Other income ​ (542) ​ (1,471) ​ (1,795) ​ (1,081) ​ (1,602) Total other (income) expense, net ​ 5,787 ​ 3,816 ​ (918) ​ (236) ​ (716) ​ ​ ​ ​ ​ ​ Net loss ​ $ (279,381) ​ $ (172,871) ​ $ (173,482) ​ $ (118,476) ​ $ (78,253) ​ ​ ​ ​ ​ ​ Basic and diluted net loss per common share ​ $ (2.42) ​ $ (1.96) ​ $ (2.30) ​ $ (1.91) ​ $ (1.60) ​ Balance Sheet Information: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, (in thousands) 2020 2019 2018 2017 2016 Cash, cash equivalents, investment securities and interest receivable ​ $ 605,426 ​ $ 140,435 ​ $ 68,901 ​ $ 84,825 ​ $ 44,969 Total assets ​ 625,642 ​ 163,014 ​ 83,616 ​ 97,381 ​ 54,782 Accumulated deficit ​ (980,597) ​ (701,216) ​ (528,345) ​ (354,863) ​ (236,387) Total equity ​ 519,350 ​ 38,615 ​ 24,036 ​ 66,993 ​ 35,868 ​ ​ 79 Table of Contents